Lazard Downgrades American Oriental (AOB) to Hold
More News related to AOB
- Halter USX China Index Up 40.88% for Second Quarter 2009
- China Aoxing Pharmaceutical Company Announces Completion of Registration Trial of Its Leading Narcotic Drug for the Treatment of Acute Moderate to Severe Cough
- China XD Plastics Enhances Board of Directors and Establishes Audit, Compensation, and Nominating Committees
- China Aoxing Pharmaceutical Company Enters Agreement to Divest Non-Core Land Property
- China Aoxing Pharmaceutical Company Reports Third Quarter Fiscal Year 2009 Financial Results
More News related to Downgrades
- HSBC Downgrades Royal Dutch Shell (RDS.B) to Neutral
- SunTrust Downgrades Scotts Miracle-Gro (SMG) to Neutral
- J.P. Morgan Downgrades Opnext (OPXT) to Underweight
- Jefferies Downgrades Discovery Lab (DSCO) Two-Notches To Underperform
- Credit Suisse Downgrades FPL Group (FPL) to Neutral
Lazard Capital downgrades American Oriental Bioengineering (NYSE: AOB) from Buy to Hold.
American Oriental Bioengineering, Inc., together with its subsidiaries, engages in the development, manufacture, and commercialization of a range of pharmaceutical and healthcare products.
Related Categories
DowngradesStocks Mentioned
+24.56Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
